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Abstract
Elevated fibroblast growth factor 23 (FGF23) is associated with cardiovascular disease in patients 
with chronic kidney disease. As a potential mediating mechanism, FGF23 induces left ventricular 
hypertrophy; however, its role in arterial calcification is less clear. In order to study this we 
quantified coronary artery and thoracic aorta calcium by computed tomography in 1501 patients 
from the Chronic Renal Insufficiency Cohort (CRIC) study within a median of 376 days 
(interquartile range 331 to 420 days) of baseline. Baseline plasma FGF23 was not associated with 
prevalence or severity of coronary artery calcium after multivariable adjustment. In contrast, 
higher serum phosphate levels were associated with prevalence and severity of coronary artery 
calcium, even after adjustment for FGF23. Neither FGF23 nor serum phosphate were consistently 
associated with thoracic aorta calcium. We could not detect mRNA expression of FGF23 or its co-
receptor, klotho, in human or mouse vascular smooth muscle cells, or normal or calcified mouse 
aorta. Whereas elevated phosphate concentrations induced calcification in vitro, FGF23 had no 
effect on phosphate uptake or phosphate-induced calcification regardless of phosphate 
concentration or even in the presence of soluble klotho. Thus, in contrast to serum phosphate, 
FGF23 is not associated with arterial calcification and does not promote calcification 
experimentally. Hence, phosphate and FGF23 promote cardiovascular disease through distinct 
mechanisms.
Keywords
phosphate; fibroblast growth factor 23; vascular calcification; vascular smooth muscle; chronic 
kidney disease
Introduction
Fibroblast growth factor 23 (FGF23) is a circulating phosphaturic hormone that is elevated 
in patients with chronic kidney disease (CKD) and is strongly associated with mortality and 
cardiovascular disease.1–6 To exert its primary physiologic functions, FGF23 binds to FGF 
receptor (FGFR)-klotho complexes in the kidney to stimulate urinary phosphate excretion 
and inhibit renal production of 1,25-dihydroxyvitamin D.7, 8 In addition to these classic, 
klotho-dependent effects, FGF23 also induces left ventricular hypertrophy via FGFR-
dependent, but klotho-independent, effects on cardiac myocytes.9 This finding raises the 
possibility that elevated FGF23 levels in CKD may also contribute to other forms of 
subclinical cardiovascular injury, which could further explain its strong association with 
cardiovascular events and mortality.
Arterial calcification is a common pattern of vascular injury in CKD that begins early in the 
course of disease and is associated with greater risk of cardiovascular events and 
mortality.10–14 Elevated serum phosphate is an independent risk factor for calcification.15 
High phosphate conditions enhance uptake of phosphate by cultured vascular smooth muscle 
cells (VSMC) through the type III Na-phosphate cotransporter, PiT-1. This induces 
osteogenic transformation and subsequent calcification.16–18 Similarly, vascular deficiency 
of klotho may also promote calcification by increasing PiT-1-dependent phosphate uptake 
by VSMCs, a phenotype that can be rescued by stimulating vascular klotho expression.19, 20
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Although FGF23 and klotho regulate phosphate balance, the specific effects of FGF23 on 
arterial calcification is less clear. Several small human studies demonstrated associations 
between higher levels of FGF23 and vascular calcification.21–25 In contrast, calcification is 
not described in transgenic animals that overexpress FGF23.26–29 Although this suggests 
that FGF23 does not induce calcification, FGF23 overexpression causes phosphate 
depletion, and may not generalize to human CKD in which FGF23 levels are elevated in 
association with normal or high serum phosphate.1 In the current translational study, we 
aimed to determine if elevated FGF23 levels are associated with prevalence and severity of 
coronary and thoracic aorta calcification in a large, carefully characterized cohort of patients 
with CKD stages 2–4; and tested whether FGF23 affects calcification directly using 
experimental models that previously established the calcifying effects of phosphate.17 In 
both the clinical and experimental analyses, we contrasted the effects of FGF23 with those 
of phosphate, and tested for independent effects of these novel, CKD-specific risk factors for 
cardiovascular disease.
Results
We studied the association between FGF23, serum phosphate, and calcification of the 
coronary arteries and thoracic aorta as assessed by computed tomography (CT) in 1501 
participants in the Chronic Renal Insufficiency Cohort (CRIC) Study. The study population 
had a mean age of 57 ± 12 years, mean estimated glomerular filtration rate (eGFR) of 47 ± 
17 ml/min/1.73 m2, 46% of participants were female, 32% were black, 22% were Hispanic 
and 47% had diabetes. The median plasma FGF23 was 134.5 RU/mL (interquartile range 
93.9 to 209.7 RU/mL). Higher plasma FGF23 levels were associated with decreased kidney 
function, other abnormalities of mineral metabolism, and traditional cardiovascular risk 
factors (Table 1). The median duration between measurement of biochemical parameters 
and assessment of calcification was 376 days (interquartile range 331 to 420 days).
Prevalence and severity of calcification
Overall, 983 participants (65%) had prevalent coronary artery calcification (CAC) and 693 
(46%) had thoracic aortic calcification (TAC), each defined as an Agatston score >0. Among 
those with prevalent CAC, 408 (42%) had a score ≤100; 233 (24%) had a score between 
101–400; and 342 (35%) had a score >400. Among those with prevalent TAC (score >0), 
325 (47%) had a score ≤100; 171 (25%) had a score between 101–400; and 197 (28%) had a 
score >400.
The unadjusted prevalence of CAC and TAC (scores > 0) was greater in higher quartiles of 
FGF23 and serum phosphate (Figure 1). Although higher plasma FGF23 was associated 
with greater CAC prevalence in models adjusted for demographics and kidney function 
(Table 2), the effect was abolished when further adjusted for traditional cardiovascular risk 
factors. FGF23 was not associated with CAC severity in any model (Table 2). In contrast, 
higher serum phosphate levels were independently associated with greater prevalence and 
greater severity of CAC in all adjusted models. Neither FGF23 nor phosphate was 
independently associated with TAC prevalence, however higher plasma FGF23 was 
associated with greater TAC severity in the subset with prevalent TAC (Table 2).
Scialla et al. Page 3
Kidney Int. Author manuscript; available in PMC 2013 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
History of cardiovascular disease was independently associated with prevalence and severity 
of CAC and TAC (p<0.01 for each) and did not modify the associations between serum 
phosphate and prevalence and severity of CAC (data not shown). In contrast, FGF23 was 
associated with TAC severity only in participants with prior cardiovascular disease (n=203; 
72% increase in TAC score per SD increase in ln FGF23; 95% CI, 24% to 141; p-
interaction=0.04). Diabetes and severity of CKD did not modify the associations of FGF23 
and serum phosphate with CAC and TAC, and there were no significant interactions 
between FGF23 and phosphate (data not shown). Since dietary phosphate intake alters 
FGF23 levels,30, 31 we evaluated the association of 24-hour urinary phosphate with 
calcification, but found no independent associations with prevalence or severity of CAC or 
TAC (Supplemental Table 1).
Sensitivity analyses
The primary results were qualitatively unchanged after excluding 74 participants who were 
using active vitamin D sterols or phosphate binders, when we additionally adjusted for 25-
hydroxyvitamin D and 1,25-hydroxyvitamin D if available (n=534), and when we adjusted 
for iothalamate GFR in lieu of eGFR (data not shown). We repeated the primary analyses 
among those with less than 1 year between biochemical measurements and assessment of 
calcification, and among those whose renal function remained unchanged (difference in 
eGFR ≤ 5ml/min/1.73m2) between measurements. In both of these sensitivity analyses, 
point estimates were similar to the primary analysis (Supplemental Tables 2 and 3).
To assess whether the results were robust to different modeling strategies, we fit 
multivariable-adjusted ordinal logistic regression models to evaluate the odds ratio of a one 
category (0; 1–100; 101–400; and >400) increase in CAC or TAC score. Consistent with the 
primary results, higher serum phosphate, but not FGF23, was associated with greater odds of 
being in a higher CAC category, and neither was associated with TAC using this approach 
(Table 3). Finally, we modeled prevalence of CAC using alternate threshold values. Similar 
to prevalence of CAC >0 (Table 2; Figure 2a), higher quartiles of serum phosphate, but not 
plasma FGF23, were associated with greater prevalence of CAC scores above versus below 
100, 400 and 800 in fully adjusted models (Figures 2b–d). Unlike TAC >0 (Table 2), higher 
quartiles of FGF23 were associated with greater prevalence of TAC >100, 400 and 800 but 
the estimates of effect were highly unstable and inconsistent across the different cut points 
(Supplemental Figure).
Mouse aorta and human vascular smooth muscle cells do not express FGF23 or klotho
Consistent with a recent report,32 we detected expression of FGF receptors (FGFR)1 and 
FGFR3 in cultured human vascular smooth muscle cells (VSMCs) by reverse transcription 
PCR (RT-PCR, data not shown). In contrast, we did not detect expression of FGF23 or its 
co-receptor, klotho in human or mouse cultured VSMCs by RT-PCR (Figure 3a). To 
investigate whether expression might be induced in CKD, we analyzed aortas from mice 
after partial renal ablation and dietary phosphate loading to promote uremic vascular 
calcification.33 FGF23 and klotho were not detected in any pooled sample of mouse aorta 
(2–3 aortas per pool) from 12 CKD mice, 6 of which had calcification as indicated by aortic 
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arch calcium content and aortic expression of the osteochondrogenic markers,33 or from 7 
healthy controls (data not shown).
FGF23 does not induce vascular calcification in vitro
Next, we tested whether high circulating levels of FGF23 that are prevalent in CKD could 
induce VSMC calcification. We treated human VSMCs and mouse aortic rings that were 
cultured in control (1–1.4 mM phosphate) and high phosphate media (2.6 mM) with 
ascending concentrations of FGF23. FGF23 had no effect on the calcium content in either 
control or high phosphate media (Figure 3b). These results were reproduced using 2 forms 
of human FGF23 (intact and mutant R176Q in concentrations of up to 50 ng/mL) in cultured 
primary human aortic VSMCs, and supported by lack of any FGF23-mediated increase in 
human VSMC protein levels of phosphorylated ERK and FRS2α, which are major signaling 
mediators downstream of klotho-dependent FGFR1 and FGFR3 activation (data not 
shown).34
Mouse aortic rings were pre-incubated with porcine pancreatic elastase for 24 hours prior to 
the 9-day calcification assay to simulate the matrix degradation that occurs in the vessels of 
CKD mice prior to uremic vascular calcification.33, 35 Similar to the findings in human 
VSMCs, FGF23 with or without soluble klotho had no significant effect on calcification of 
mouse aortic rings cultured under high phosphate conditions (Figure 3c).
FGF23 with and without soluble klotho has no effect on VSMC phosphate uptake
FGF23 regulates expression of type II sodium-dependent phosphate cotransporters in the 
kidney,36 but its effect on the type III sodium-dependent phosphate cotransporters, PiT-1 
and PiT-2, that mediate phosphate transport in VSMCs is unknown. We tested whether 
FGF23 regulates phosphate transport in VSMC by examining radiolabeled phosphate uptake 
in the presence of sodium chloride versus choline chloride to calculate sodium-dependent 
uptake. FGF23 (50 ng/mL) had no significant effect on phosphate uptake in the presence or 
absence of soluble klotho (50 ng/mL), in either mouse or human VSMCs (Figure 4).
Discussion
Elevated FGF23 levels were not consistently associated with coronary or thoracic aorta 
calcification in patients with CKD stages 2–4 enrolled in the CRIC study. In contrast, higher 
levels of serum phosphate were strongly associated with CAC independent of FGF23. The 
lack of association of FGF23 with arterial calcification is supported by our experimental 
data that demonstrated no expression of FGF23 in human and mouse VSMCs, or in normal 
or calcified mouse aortas. Furthermore, exogenous FGF23 neither augmented phosphate 
uptake nor induced calcification of cultured human VSMCs regardless of the phosphate 
concentration of the media and whether or not exogenous soluble klotho was added. To our 
knowledge, these are the first data to demonstrate an adverse effect of serum phosphate on 
the cardiovascular system independent of and exceeding the effect of FGF23. Juxtaposed 
with our previous finding that FGF23 can induce left ventricular hypertrophy,9 these data 
suggest that phosphate and FGF23 play distinct roles in the pathogenesis of cardiovascular 
disease in CKD and that future therapeutic strategies should target both factors.
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Prior experimental literature supports a direct role of phosphate in promoting arterial 
calcification. Incubation of VSMCs in phosphate-enriched growth media induced 
differentiation into an osteoblastic phenotype with subsequent calcification,16–18 and there 
was decreased calcification when phosphate uptake was blocked.16 In a mouse model of 
CKD, arterial medial calcification can be induced by a high phosphate diet,33 and transient 
elevations in serum phosphate are sufficient to drive this process.35 The pathogenic role of 
FGF23 in calcification in vivo has been less clear in experimental settings. Calcification 
occurs in animal models with elevated FGF23 levels, but only in the setting of secondary 
FGF23 excess with hyperphosphatemia,37, 38 and not in models of primary FGF23 excess in 
which serum phosphate is low.26–29 FGF23-ablated mice and CKD rats in which FGF23 
was neutralized demonstrate rapidly fatal vascular calcification associated with severe 
hyperphosphatemia.39, 40 Collectively, these data, along with our current results, implicate 
phosphate rather than FGF23 as a critical factor driving calcification.41
Our results provide new insight that may help explain the seemingly contradictory results of 
prior human studies relating FGF23 and arterial calcification.21–25, 42, 43 We observed that 
the association of higher plasma FGF23 with presence of CAC in minimally adjusted 
analyses did not persist after adjustment for traditional coronary risk factors that are 
associated with elevated FGF23,30 and that FGF23 was not associated with CAC severity in 
any analysis. Unlike these generally congruent results, analyses of TAC prevalence versus 
TAC severity yielded divergent results. Although FGF23 was not associated with presence 
versus absence of TAC, and the ordinal logistic regression approach that included all 
participants found no association, FGF23 was associated with TAC severity among those 
with non-zero scores. This could be interpreted to suggest that FGF23 may promote the 
progression, but not the genesis, of calcification in large vessels such as the aorta. 
Alternatively, the isolated association of elevated FGF23 with TAC severity may represent a 
statistical “false positive” that resulted from the complexity of modeling "zero inflated" data, 
such as the Agatston score44 and the relatively large number of tests we performed. Our 
negative experimental data support the latter conclusion. These observations emphasize that 
clinical studies of FGF23 and calcification are especially sensitive to how calcification is 
defined, which vascular bed is imaged, whether prevalence or severity is modeled, and how 
the large numbers of individuals with calcification scores of zero are handled 
methodologically.
By nesting within the CRIC study, we could adjust for a comprehensive set of clinical 
covariates in the largest analysis of FGF23 and calcification in CKD to date. Based on the 
confidence intervals we report, we can statistically exclude an association as small as a 6% 
increase in the prevalence and 16% increase in the severity of CAC per standard deviation 
increase in FGF23. Thus, if we missed an effect, it would have to be extremely small and 
perhaps of limited clinical relevance. Our study also has certain limitations. The lag of up to 
two years between biochemical measurements and assessment of calcification may have 
affected our ability to detect associations. However, in support of the validity of our results, 
the point estimates for FGF23 and phosphate were similar in the overall population and the 
subgroup with a shorter time lag between measurements. In addition, we were not able to 
fully adjust for vitamin D levels in our primary models. However, most prior studies did not 
adjust for vitamin D levels at all, and the subgroup analysis in which adjustment for vitamin 
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D had minimal effect on point estimates suggests it is unlikely that more complete 
adjustment would have exposed a significant association between FGF23 and CAC. Finally, 
in this study we were only able to study anatomic, and not functional, changes in the 
vasculature, which have been associated with FGF23.45
Our experimental data differ somewhat from previous studies. Unlike a recent study that 
reported transmembrane klotho protein expression in healthy human vessels,19 we could not 
detect klotho expression in human VSMCs, perhaps due to different culture conditions. 
Furthermore, we did not identify an anti-calcification effect of FGF23 in the presence of 
klotho as noted previously,19 however this may be due to our use of exogenous soluble 
klotho rather than induction of endogenous expression. In contrast to prior reports,20 we did 
not detect decreased calcification in response to soluble klotho. This could be due to species-
specific differences or the concentrations of soluble klotho that were studied. Despite their 
differences, it is important to note that none of the mechanistic studies has yet to identify a 
direct pro-calcification effect of FGF23 on VSMCs, suggesting that induction of vascular 
calcification is not likely to be a major disease pathway explaining the strong clinical 
associations between FGF23 and mortality.
Early studies that identified elevated FGF23 as a risk factor for mortality proposed that 
FGF23 could represent a superior biomarker of phosphate-related toxicity relative to serum 
phosphate.2 The results of the current study advance an intermediate paradigm in which 
FGF23 and phosphate may exert distinct effects on the cardiovascular system, with FGF23 
acting primarily on the heart and phosphate acting on the arterial tree. Furthermore, by 
demonstrating lack of a pro-calcification effect of FGF23, these well-powered “negative” 
data help to clarify the end-organ specificity of FGF23 toxicity and provide novel insight 
into the cardiovascular impact of disordered phosphate metabolism in CKD.
Methods
Study population
The CRIC Study is a prospective cohort study of 3939 adult men and women (ages 21–74 
years) with mild to moderate CKD (eGFR 20–70 ml/min/1.73 m2) enrolled from seven 
clinical centers in the United States between 2003 and 2008, as described previously.46, 47 A 
random subcohort of 2026 participants underwent CT for quantification of CAC and TAC 
within 4 years after enrollment. Twenty-nine participants were excluded from this analysis 
because baseline plasma samples were not available for FGF23 measurement. An additional 
496 were excluded because CT was performed more than 2 years after FGF23 was assessed 
at the baseline visit or after dialysis was initiated, leaving a total of 1501 participants for this 
analysis. The study was approved by the Institutional Review Boards of participating 
clinical centers, and each participant provided written informed consent.
Data collection
We measured FGF23 in stored plasma samples from the baseline visit using a second 
generation C-terminal assay (Immutopics, San Clemente, CA). Measurements were 
performed in duplicate in a central laboratory after a single thaw (coefficient of variation 
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<10%). We used standard assays to measure serum creatinine, albumin, calcium, phosphate, 
urinary albumin, and 24-hour urinary phosphate centrally. We corrected serum calcium for 
hypoalbuminemia.48 We measured plasma parathyroid hormone using a total intact assay 
(Scantibodies, Santee, CA). We analyzed renal function using the CRIC estimating equation 
for eGFR that was derived from direct measurements of iothalamate clearance (iGFR) in a 
subgroup of participants.49, 50
All participants underwent two concurrent CT scans with either Electron Beam CT scanner 
(GE Medical Systems), or multidetector CT scanner. We used commercially available 
software (Neo Imagery Technologies, Inc) to quantify calcification according to the 
Agatston criteria.51 Total CAC score was determined as the sum of scores from the left 
main, left anterior descending, left circumflex, and right coronary arteries. Total TAC score 
was determined as the sum of the scores from the ascending and descending thoracic aorta 
that were visible on the coronary CT scans, as has been done previously.52 Final scores were 
calculated as the mean of the two scans.53
Analysis of human data
We compared characteristics of the study population across quartiles of FGF23 using 
ANOVA, Pearson’s χ2 test, or Kruskal-Wallis test, as appropriate. For continuous analyses, 
we transformed FGF23 as the natural logarithm (ln), and standardized ln FGF23, serum 
phosphate, and 24-hour urinary phosphate to their respective standard deviations to facilitate 
comparison.
We estimated the association of FGF23 and serum phosphate with prevalence of CAC and 
TAC (score >0) using Poisson regression with robust variance estimation.54 We sequentially 
adjusted for demographics (age, sex, race, ethnicity), kidney function (eGFR, ln-transformed 
urine albumin-to-creatinine ratio), clinical center, traditional cardiovascular risk factors 
(prior cardiovascular disease, diabetes, hypertension, hypercholesterolemia, former or 
current smoking, categories of body mass index), and corrected serum calcium and ln-
transformed parathyroid hormone levels. Models of serum phosphate were analyzed before 
and after adjustment for FGF23, and models of FGF23 before and after adjustment for 
serum phosphate. We confirmed that the assumptions of a Poisson distribution were met by 
comparing our results to those obtained using negative binomial regression.
Among participants with calcification scores >0, we analyzed the association of FGF23 and 
serum phosphate with severity of calcification using linear regression to model the ln-
transformed score with sequential adjustments as described above. Regression coefficients 
(β) were expressed as the percent difference in CAC or TAC per 1 standard deviation 
increase in either ln FGF23 or serum phosphate by performing the inverse logarithm 
(eβ).55, 56 We confirmed adequate model fit using residual analysis.
To evaluate for effect modification of prevalence and severity of calcification, we performed 
analyses stratified by history of prior cardiovascular disease, diabetes, and CKD severity 
(eGFR above versus below 45 ml/min/1.73m2). We also tested for interaction between 
FGF23 and phosphate.
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In secondary analyses, we evaluated the association of calcification with 24-hour urinary 
phosphate as a surrogate of dietary phosphate intake. We repeated the main analyses after 
excluding 74 study participants who were treated with active vitamin D sterols or phosphate 
binders. We adjusted for directly measured iGFR in place of eGFR in the subset of 
participants in whom iGFR was available (n=1034), and for 25-hydroxyvitamin D and 1,25-
hydroxyvitamin D when available (n=534). We determined the association of FGF23 and 
serum phosphate with the prevalence of CAC and TAC using alternate threshold values (0, 
100, 400 and 800), and used ordinal logistic regression to model risk of being in higher 
severity categories (0; 1–100; 101–400; and >400). Finally, to confirm that our results were 
not biased by the time elapsed between measurement of FGF23, phosphate and CT scans, 
we fit primary models in the population with <1 year between measurements (n=597) and 
among those whose eGFR was unchanged (difference ≤ 5ml/min/1.73m2; n=842) between 
measurements. All analyses were performed using Stata 11.1 (StataCorp; College Station, 
TX).
Reverse transcription PCR (RT-PCR)
Mouse aortas isolated from an experiment involving phosphate-induced uremic vascular 
calcification33 were examined for FGF23 and klotho expression. RNA from the aortas of 
CKD and healthy control mice was extracted using TRIzol/chloroform followed by the 
RNeasy Mini Kit (Qiagen); each sample was pooled from 2 to 3 aortas. First-strand cDNA 
was made from total RNA using the Omniscript Reverse Transcriptase kit (Qiagen). Further, 
total RNA from cultured human and mouse VSMCs was extracted using the RNeasy Mini 
Kit, and used to make cDNA using the Omniscript Reverse Transcriptase kit (Qiagen).
We tested for human FGF23 and klotho expression using intron-spanning primers that have 
previously been described.32 We designed intron-spanning mouse FGF23 and klotho 
primers, using mouse calvarial cDNA (for FGF23) and kidney cDNA (for klotho) as 
positive controls. Mouse FGF23 primer sequences: forward 5'-
TGGGCACTGCTAGAGCCTAT-3' and reverse 5'-CTTCGAGTCATGGCTCCTGT-3’. 
Mouse klotho primer sequences: forward 5’-ATTGATGGCGACTACCCAGA-3’ and 
reverse 5’-AAGGAGGAAAGCCATTGTCC-3’.
FGF23 and klotho reagents
Intact human FGF23 and the mutant form, R176Q, of human FGF23 (P-0333) were 
provided by Genzyme (Cambridge, MA). Recombinant mouse FGF23 (2629-FG/CF) and 
klotho (1819-KL) were purchased from R&D Systems (Minneapolis, MN). In our 
experiments, we utilized doses of FGF23 and klotho that were in the upper end of the 
physiologic range (2 ng/mL) in prior human and animal studies,2, 33, 57–59 and also 
examined higher doses (20 and 50 ng/mL) for certain experiments.
Phosphate-induced calcification of cultured human VSMCs
Primary human aortic VSMCs were obtained from Clonetics Corporation (Palo Alto, CA). 
The cells were isolated, characterized, and immortalized as previously described.17 Cells 
were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen, Carlsbad, 
CA) containing 100 U/mL penicillin, 100 µg/mL streptomycin, 15% FBS and 1.4 mM 
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phosphate. Calcification was induced by supplementing the media with NaH2PO4/Na2HPO4 
to a final concentration of 2.6 mM phosphate. Various concentrations of native and mutant 
human FGF23 were tested for effect on calcification (1, 10, 20 and 50 ng/mL). Calcium 
content of the cultures was determined using the o-cresolphthalein complexone method and 
normalized to protein content as previously described.17
Phosphate-induced calcification of cultured mouse aortic rings
Mouse aortas were harvested from 12–14 week old DBA/2J mice and perivascular fat was 
removed. Aortas were cut into 2–3 mm length aortic rings, which were cultured in 
individual wells on a 24-well plate, in DMEM containing 100 U/mL penicillin, 100 µg/mL 
streptomycin, 0.25 µg/mL fungizone, 5% FBS and 1 mM phosphate. Aortic rings were 
incubated in 0.01 U/mL porcine pancreatic elastase (E7885, Sigma) for 24 hours to initiate 
elastin breakdown, which is prevalent in the vessels of CKD mice and precedes uremic 
vascular calcification.35 This elastase treatment protocol results in more reliable 
calcification of aortic rings (Lau and Giachelli, unpublished data). Calcification was induced 
by culture in high phosphate 2.6 mM media for 9 days, and two concentrations of mouse 
FGF23 with and without mouse klotho were tested (2 and 20 ng/mL). At the termination of 
the experiment, aortic rings were snap-frozen in liquid nitrogen, lyophilized, and decalcified 
with 0.6 N HCl at 37°C for 24 hours. The calcium content of the supernatant was 
determined colorimetrically with the ocresolphthalein complexone kit from Teco 
Diagnostics (Anaheim, CA). Aortic calcium content was normalized to the dry weight of the 
tissue and expressed as µg Ca/mg dry weight.
Phosphate uptake assays
Mouse primary aortic VSMCs and human aortic VSMCs were passaged in DMEM 
supplemented with 10% FBS, 100 U/mL penicillin, 100 µg/mL streptomycin and 0.25 
µg/mL fungizone. The mouse and human VSMCs were seeded into 12-well and 24-well 
tissue culture plates respectively at 2.5 × 104 cells per well. After 2 days of growth, the cells 
were washed with modified Earle’s Balanced Salt Solution (EBSS) containing 146 mM 
sodium chloride for total uptake or 146 mM choline chloride to measure sodium 
independent uptake.
Cells were then incubated for 20 minutes in EBSS containing 0.05 mM inorganic phosphate 
and 3 µCi/ml 33P orthophosphoric acid with or without FGF23 and klotho. Mouse VSMCs 
were incubated with 50 ng/mL mouse FGF23 and 50 ng/mL mouse klotho, while human 
cells were treated with 50 ng/mL mutant human FGF23 (R176Q) and 50 ng/mL mouse 
klotho. Each experimental condition was performed in triplicate. Finally, cells were lysed in 
0.2 N NaOH for 20 minutes and neutralized with HCl. Radioactivity was measured using a 
liquid scintillation counter and was normalized to protein content (Pierce Micro BCA 
Protein Assay Kit, Thermo Scientific, Rockford, IL).
Analysis of experimental data
Statistical analyses were performed using SPSS software v16.0 (SPSS, Chicago, IL). Group 
means were compared using one-way ANOVA with Bonferroni post-hoc analysis, with 
significance set at p<0.05.
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Figure 1. 
Prevalence of coronary artery calcium and thoracic aorta calcium scores > 0 across quartiles 
of plasma fibroblast growth factor 23 (n=1501) and serum phosphate (n=1470).
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Figure 2. 
Adjusted prevalence ratios (black squares) and 95% confidence intervals (vertical bars) of 
coronary artery calcium (CAC) score greater than threshold values of (A) >0; (B) >100; (C) 
>400; and (D) >800. Results are presented by quartiles of plasma fibroblast growth factor 23 
(FGF23) and serum phosphate with quartile 1 serving as the reference group. All models are 
adjusted for age, sex, race, ethnicity, eGFR, urine albumin-to-creatinine ratio, prior 
cardiovascular disease, diabetes, smoking, hypertension, hypercholesterolemia, body mass 
index, parathyroid hormone, corrected serum calcium, and clinical center. Models of FGF23 
were additionally adjusted for serum phosphate. Models of serum phosphate were 
additionally adjusted for FGF23. P-values represent tests of trend across quartiles.
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Figure 3. 
(A) RT-PCR did not detect fibroblast growth factor 23 (FGF23) or klotho cDNA in human 
vascular smooth muscle cells (VSMCs), using primer sets that have previously been 
described.32 FGF23 positive control from plasmid cDNA (expected band size 649 bp), and 
klotho positive control from human kidney cDNA (expected band size 349 bp).
(B) In cultured human VSMCs, FGF23 did not induce calcification under control conditions 
(1.4 mM phosphate) and did not augment calcification under high-phosphate conditions (2.6 
mM phosphate). Data are mean ± s.d. and p-values for the two phosphate conditions are 
shown.
(C) FGF23 with or without soluble klotho did not affect phosphate-induced calcification of 
mouse aortic rings (n = 5 per group). Data are mean ± s.d. and p-value for the high-
phosphate groups is shown.
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Figure 4. 
Fibroblast growth factor 23 (50 ng/mL) with or without klotho (50 ng/mL) had no 
significant effect on sodium-dependent phosphate uptake in both mouse and human VSMCs. 
Data expressed as mean ± s.d. and p-values for the human and mouse data sets are 
presented.
Scialla et al. Page 23
Kidney Int. Author manuscript; available in PMC 2013 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Scialla et al. Page 24
Ta
bl
e 
1
Ch
ar
ac
te
ris
tic
s o
f t
he
 st
ud
y 
po
pu
la
tio
n 
by
 q
ua
rti
le
s o
f p
la
sm
a 
fib
ro
bl
as
t g
ro
w
th
 fa
ct
or
 2
3
Fi
br
ob
la
st
 G
ro
w
th
 F
ac
to
r 2
3 
(R
U/
ml
)
C
ha
ra
ct
er
ist
ic
m
ea
n
 ±
 S
D
 o
r n
 (%
)
Qu
ar
til
e 1
1.
8–
93
.8
N
=3
76
Qu
ar
til
e 2
93
.9
–1
34
.4
N
=3
76
Qu
ar
til
e 3
13
4.
5–
20
9.
6
N
=3
74
Qu
ar
til
e 4
20
9.
7–
53
54
.8
N
=3
75
p*
D
em
og
ra
ph
ic
s
 
 
 
 
A
ge
 (y
ea
rs)
54
 ±
 1
2
57
 ±
 1
2
59
 ±
 1
1
57
 ±
 1
1
<
0.
01
 
 
 
 
Fe
m
al
e 
se
x
14
5 
(38
.6)
16
7 
(44
.4)
16
9 
(45
.2)
20
8 
(55
.5)
<
0.
01
 
 
 
 
R
ac
e
0.
01
 
 
 
 
 
 
W
hi
te
19
2 
(51
.0)
17
6 
(46
.8)
18
0 
(48
.1)
15
5 
(41
.3)
 
 
 
 
 
 
B
la
ck
11
9 
(31
.7)
12
3 
(32
.7)
99
 (2
6.5
)
13
6 
(36
.3)
 
 
 
 
 
 
O
th
er
65
 (1
7.3
)
77
 (2
0.5
)
95
 (2
5.4
)
84
 (2
2.4
)
 
 
 
 
H
isp
an
ic
 e
th
ni
ci
ty
55
 (1
4.6
)
67
 (1
7.8
)
96
 (2
5.7
)
10
5 
(28
.0)
<
0.
01
Tr
ad
iti
on
al
 C
V
 R
isk
 F
ac
to
rs
 
 
 
 
Pr
io
r C
V
D
50
 (1
3.3
)
75
 (2
0.0
)
90
 (2
4.1
)
13
3 
(35
.5)
<
0.
01
 
 
 
 
D
ia
be
te
s
11
2 
(29
.8)
15
7 
(41
.8)
20
8 
(55
.6)
23
0 
(61
.3)
<
0.
01
 
 
 
 
Fo
rm
er
/c
ur
re
nt
 sm
ok
er
17
0 
(45
.2)
18
8 
(50
.0)
18
0 
(48
.1)
20
2 
(53
.9)
0.
12
 
 
 
 
B
od
y 
m
as
s i
nd
ex
 (k
g/m
2 )
<
0.
01
 
 
 
 
 
 
<
25
81
 (2
1.6
)
77
 (2
0.5
)
53
 (1
4.2
)
49
 (1
3.1
)
 
 
 
 
 
 
25
–2
9.
9
12
2 
(32
.5)
12
5 
(33
.2)
12
8 
(34
.2)
83
 (2
2.1
)
 
 
 
 
 
 
30
–3
9.
9
15
1 
(40
.3)
14
5 
(38
.6)
15
4 
(41
.2)
18
0 
(48
.0)
 
 
 
 
 
 
≥4
0
21
 (5
.6)
29
 (7
.7)
39
 (1
0.4
)
63
 (1
6.8
)
 
 
 
 
H
yp
er
te
ns
io
n
27
0 
(71
.8)
31
3 
(83
.2)
33
7 
(90
.1)
34
9 
(93
.1)
<
0.
01
 
 
 
 
H
yp
er
ch
ol
es
te
ro
le
m
ia
24
8 
(66
.0)
27
5 
(73
.1)
31
1 
(83
.4)
30
7 
(81
.9)
<
0.
01
K
id
ne
y 
Fu
nc
tio
n
 
 
 
 
Es
tim
at
ed
 G
FR
 (m
l/m
in/
1.7
3m
2 )
60
.3
 ±
 1
7.
1
50
.8
 ±
 1
5.
6
41
.6
 ±
 1
1.
7
34
.8
 ±
 1
3.
0
<
0.
01
 
 
 
 
CK
D
 st
ag
e
<
0.
01
 
 
 
 
 
 
2 
(eG
FR
 ≥ 
60
 m
l/m
in
/1
.7
3m
2 )
18
1 
(48
.1)
95
 (2
5.3
)
20
 (5
.4)
9 
(2.
4)
 
 
 
 
 
 
3a
 (e
GF
R 
45
–5
9 m
l/m
in/
1.7
3m
2 )
12
4 
(33
.0)
13
6 
(36
.3)
12
1 
(32
.4)
64
 (1
7.1
)
 
 
 
 
 
 
3b
 (e
GF
R 
30
–4
4 m
l/m
in/
1.7
3m
2 )
65
 (1
7.3
)
11
4 
(30
.4)
17
0 
(45
.5)
15
3 
(40
.8)
 
 
 
 
 
 
4/
5 
(eG
FR
 <3
0 m
l/m
in/
1.7
3m
2 )
6 
(1.
6)
30
 (8
.0)
63
 (1
6.8
)
14
9 
(39
.7)
Kidney Int. Author manuscript; available in PMC 2013 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Scialla et al. Page 25
Fi
br
ob
la
st
 G
ro
w
th
 F
ac
to
r 2
3 
(R
U/
ml
)
C
ha
ra
ct
er
ist
ic
m
ea
n
 ±
 S
D
 o
r n
 (%
)
Qu
ar
til
e 1
1.
8–
93
.8
N
=3
76
Qu
ar
til
e 2
93
.9
–1
34
.4
N
=3
76
Qu
ar
til
e 3
13
4.
5–
20
9.
6
N
=3
74
Qu
ar
til
e 4
20
9.
7–
53
54
.8
N
=3
75
p*
 
 
 
 
U
rin
ar
y 
A
CR
 (m
g/g
)†
15
 (5
, 1
40
)
31
 (6
, 3
41
)
10
1 
(11
, 7
82
)
22
4 
(29
, 1
63
2)
<
0.
01
 
 
 
 
 
 
<
30
21
5 
(59
.4)
17
3 
(48
.7)
14
5 
(40
.2)
89
 (2
5.0
)
<
0.
01
 
 
 
 
 
 
30
–2
99
78
 (2
1.6
)
88
 (2
4.8
)
77
 (2
1.3
)
10
0 
(28
.1)
 
 
 
 
 
 
30
0–
99
9
45
 (1
2.4
)
47
 (1
3.2
)
65
 (1
8.0
)
49
 (1
3.8
)
 
 
 
 
 
 
≥1
00
0
24
 (6
.6)
47
 (1
3.2
)
74
 (2
0.5
)
11
8 
(33
.2)
M
in
er
al
 M
et
ab
ol
ism
 P
ar
am
et
er
s
 
 
 
 
Co
rre
ct
ed
 se
ru
m
 c
al
ci
um
 (m
g/d
l)
9.
18
 ±
 0
.4
0
9.
18
 ±
 0
.4
4
9.
27
 ±
 0
.4
8
9.
32
 ±
 0
.4
8
<
0.
01
 
 
 
 
Se
ru
m
 p
ho
sp
ha
te
 (m
g/d
l)
3.
39
 ±
 0
.5
3
3.
63
 ±
 0
.5
6
3.
81
 ±
 0
.6
2
4.
08
 ±
 0
.8
1
<
0.
01
 
 
 
 
Pa
ra
th
yr
oi
d 
ho
rm
on
e 
(pg
/m
l)†
41
 (2
9, 
61
)
49
 (3
2, 
74
)
54
 (3
8, 
87
)
77
 (4
5, 
13
5)
<
0.
01
 
 
 
 
Pa
ra
th
yr
oi
d 
ho
rm
on
e 
>6
5 
pg
/m
l
78
 (2
1.1
)
11
6 
(31
.4)
14
7 
(39
.7)
21
9 
(59
.2)
<
0.
01
 
 
 
 
U
se
 o
f a
ct
iv
e 
vi
ta
m
in
 D
5 
(1.
3)
4 
(1.
1)
13
 (3
.5)
15
 (4
.0)
0.
02
 
 
 
 
U
se
 o
f p
ho
sp
ha
te
 b
in
de
rs
5 
(1.
3)
7 
(1.
9)
14
 (3
.8)
19
 (5
.1)
<
0.
01
*
p-
va
lu
e 
by
 a
no
va
 o
r k
ru
sk
al
-w
al
lis
 te
st 
(co
nti
nu
ou
s v
ari
ab
les
) a
nd
 C
hi-
sq
ua
red
 (c
ate
go
ric
al 
va
ria
ble
s)
† p
re
se
nt
ed
 a
s m
ed
ia
n 
(IQ
R)
CV
D
, c
ar
di
ov
as
cu
la
r d
ise
as
e;
 G
FR
, g
lo
m
er
ul
ar
 fi
ltr
at
io
n 
ra
te
; C
K
D
, c
hr
on
ic
 k
id
ne
y 
di
se
as
e;
 A
CR
, a
lb
um
in
 to
 c
re
at
in
in
e 
ra
tio
Kidney Int. Author manuscript; available in PMC 2013 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Scialla et al. Page 26
Ta
bl
e 
2
A
dju
ste
d a
sso
cia
tio
n o
f f
ibr
ob
las
t g
row
th 
fac
tor
 23
 (F
GF
23
) a
nd
 se
rum
 ph
osp
ha
te 
wi
th 
pre
va
len
ce 
an
d s
ev
eri
ty 
of 
co
ron
ary
 ar
ter
y a
nd
 th
ora
cic
 ao
rta
 
ca
lc
ifi
ca
tio
n
C
or
on
ar
y 
A
rt
er
y 
C
al
ci
fic
at
io
n
Th
or
ac
ic
 A
or
ta
 C
al
ci
fic
at
io
n
M
od
el
*
Pr
ev
al
en
ce
Pr
ev
al
en
ce
 r
at
io
p
Se
ve
ri
ty
†
%
 d
iff
er
en
ce
 in
 C
A
C
p
Pr
ev
al
en
ce
Pr
ev
al
en
ce
 r
at
io
p
Se
ve
ri
ty
†
%
 d
iff
er
en
ce
 in
 T
A
C
p
D
em
og
ra
ph
ic
, k
id
ne
y 
fu
nc
tio
n 
ad
jus
ted
Ln
 F
G
F2
3 
(pe
r S
D‡
)
 
 
 
−
Ph
os
ph
at
e 
(n=
14
34
)
1.
05
 (1
.01
 to
 1.
09
)
 
 
0.
02
5%
 (−
10
% 
to 
22
%)
 
 
0.
57
1.
02
 (0
.97
 to
 1.
08
)
0.
47
30
%
 (8
% 
to 
56
%)
<
0.
01
 
 
 
+
Ph
os
ph
at
e 
(n=
14
04
)
1.
04
 (1
.00
 to
 1.
08
)
 
 
0.
04
1%
 (−
13
% 
to 
18
%)
 
 
0.
85
1.
02
 (0
.96
 to
 1.
08
)
0.
60
34
%
 (1
1%
 to
 62
%)
<
0.
01
Ph
os
ph
at
e 
(pe
r S
D‡
)
 
 
 
−
FG
F2
3 
(n=
14
04
)
1.
09
 (1
.05
 to
 1.
13
)
<
0.
01
37
%
 (1
9%
 to
 58
%)
<
0.
01
1.
07
 (1
.01
 to
 1.
13
)
0.
03
13
%
 (−
5%
 to
 35
%)
 
 
0.
16
 
 
 
+
FG
F2
3 
(n=
14
04
)
1.
08
 (1
.05
 to
 1.
13
)
<
0.
01
37
%
 (1
8%
 to
 58
%)
<
0.
01
1.
06
 (1
.00
 to
 1.
13
)
0.
03
9%
 (−
8%
 to
 30
%)
 
 
0.
33
+
 T
ra
di
tio
na
l r
isk
 fa
ct
or
s
Ln
 F
G
F2
3 
(pe
r S
D‡
)
 
 
 
−
Ph
os
ph
at
e 
(n=
14
32
)
1.
02
 (0
.98
 to
 1.
06
)
 
 
0.
24
0%
 (−
14
% 
to 
16
%)
 
 
>
0.
99
1.
00
 (0
.94
 to
 1.
06
)
0.
97
24
%
 (4
% 
to 
48
%)
 
 
0.
02
 
 
 
+
Ph
os
ph
at
e 
(n=
14
02
)
1.
02
 (0
.98
 to
 1.
06
)
 
 
0.
32
−
2%
 (−
16
% 
to 
14
%)
 
 
0.
78
1.
00
 (0
.94
 to
 1.
05
)
0.
90
29
%
 (7
% 
to 
55
%)
<
0.
01
Ph
os
ph
at
e 
(pe
r S
D‡
)
 
 
 
−
FG
F2
3 
(n=
14
02
)
1.
06
 (1
.02
 to
 1.
10
)
<
0.
01
26
%
 (1
0%
 to
 46
%)
<
0.
01
1.
05
 (0
.99
 to
 1.
11
)
0.
09
12
%
 (−
6%
 to
 34
%)
 
 
0.
19
 
 
 
+
FG
F2
3 
(n=
14
02
)
1.
06
 (1
.02
 to
 1.
10
)
<
0.
01
27
%
 (1
0%
 to
 46
%)
<
0.
01
1.
05
 (0
.99
 to
 1.
11
)
0.
08
9%
 (−
9%
 to
 29
%)
 
 
0.
35
+
 C
or
re
ct
ed
 ca
lc
iu
m
 a
nd
 P
TH
Ln
 F
G
F2
3 
(pe
r S
D‡
)
 
 
 
−
Ph
os
ph
at
e 
(n=
13
84
)
1.
02
 (0
.99
 to
 1.
07
)
 
 
0.
22
2%
 (−
12
% 
to 
18
%)
 
 
0.
80
0.
99
 (0
.94
 to
 1.
05
)
0.
84
31
%
 (9
% 
to 
58
%)
<
0.
01
 
 
 
+
Ph
os
ph
at
e 
(n=
13
72
)
1.
02
 (0
.98
 to
 1.
06
)
 
 
0.
36
−
1%
 (−
15
% 
to 
16
%)
 
 
0.
93
0.
99
 (0
.94
 to
 1.
05
)
0.
81
31
%
 (9
% 
to 
58
%)
<
0.
01
Ph
os
ph
at
e 
(pe
r S
D‡
)
 
 
 
−
FG
F2
3 
(n=
13
72
)
1.
06
 (1
.02
 to
 1.
10
)
<
0.
01
26
%
 (9
% 
to 
46
%)
<
0.
01
1.
04
 (0
.98
 to
 1.
11
)
0.
15
12
%
 (−
6%
 to
 34
%)
 
 
0.
21
 
 
 
+
FG
F2
3 
(n=
13
72
)
1.
06
 (1
.02
 to
 1.
10
)
<
0.
01
26
%
 (9
% 
to 
46
%)
<
0.
01
1.
04
 (0
.99
 to
 1.
11
)
0.
14
8%
 (−
10
% 
to 
29
%)
 
 
0.
40
*
D
em
og
ra
ph
ic
 a
nd
 k
id
ne
y 
fu
nc
tio
n 
ad
jus
ted
 m
od
el 
inc
lud
es 
ag
e, 
sex
, ra
ce,
 H
isp
an
ic 
eth
nic
ity
, e
GF
R,
 ln
-tr
an
sfo
rm
ed
 ur
ine
 al
bu
mi
n-t
o-c
rea
tin
ine
 ra
tio
 an
d c
lin
ica
l c
en
ter
+
 tr
ad
iti
on
al
 ri
sk
 fa
ct
or
 m
od
el
 a
dd
iti
on
al
ly
 a
dju
ste
d f
or 
pri
or 
car
dio
va
scu
lar
 di
sea
se,
 di
ab
ete
s, h
yp
ert
en
sio
n, 
hy
pe
rch
ole
ste
rol
em
ia,
 sm
ok
ing
, a
nd
 ca
teg
ori
es 
of 
bo
dy
 m
ass
 in
de
x
+
 c
or
re
ct
ed
 c
al
ci
um
 a
nd
 P
TH
 m
od
el
 a
dd
iti
on
al
ly
 a
dju
ste
d f
or 
co
rre
cte
d s
eru
m 
cal
ciu
m 
an
d l
n-t
ran
sfo
rm
ed
 PT
H
Kidney Int. Author manuscript; available in PMC 2013 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Scialla et al. Page 27
+
Ph
os
ph
at
e 
is 
ad
di
tio
na
lly
 a
dju
ste
d f
or 
ser
um
 ph
osp
ha
te
+
FG
F2
3 
is 
ad
di
tio
na
lly
 a
dju
ste
d f
or 
ln-
tra
nsf
orm
ed
 FG
F2
3
† a
m
o
n
g 
th
os
e 
w
ith
 n
on
-z
er
o 
A
ga
tst
on
 sc
or
e 
(n=
92
0 f
or 
CA
C;
 65
3 f
or 
TA
C 
in 
de
mo
gra
ph
ic 
an
d k
idn
ey
 fu
nc
tio
n a
dju
ste
d m
od
el 
inc
lud
ing
 bo
th 
ser
um
 ph
osp
ha
te 
an
d F
GF
23
)
‡ S
D
 o
f L
n 
FG
F2
3=
0.
72
; S
D
 o
f p
ho
sp
ha
te
=0
.6
9
Kidney Int. Author manuscript; available in PMC 2013 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Scialla et al. Page 28
Table 3
Adjusted association of fibroblast growth factor 23 (FGF23) and serum phosphate with categories of coronary 
artery calcium (CAC) and thoracic aorta calcium (TAC) scores using ordinal logistic regression (n=1384)
Model*
Odds ratio for 1 unit
increase in CAC category† p
Odds ratio for 1 unit
increase in TAC category† p
Ln FGF23 (per SD‡)
   −Phosphate 1.05 (0.93–1.20)   0.43 1.07 (0.94–1.21) 0.33
   +Phosphate 1.02 (0.90–1.16)   0.74 1.06 (0.93–1.21) 0.38
Phosphate (per SD‡)
   −FGF23 1.29 (1.14–1.46) <0.01 1.12 (0.98–1.27) 0.10
   +FGF23 1.29 (1.13–1.46) <0.01 1.11 (0.97–1.26) 0.13
*
adjusted for age, sex, race, Hispanic ethnicity, eGFR, ln-transformed urine albumin-to-creatinine ratio, prior cardiovascular disease, diabetes, 
hypertension, hypercholesterolemia, smoking, body mass index, corrected serum calcium, ln-transformed PTH and clinical center
+Phosphate is additionally adjusted for serum phosphate
+FGF23 is additionally adjusted for ln-transformed FGF23
†Categories defined as: category 1, score=0; category 2, score 1–100; category 3, score 101–400; category 4, score > 400.
‡SD of Ln FGF23=0.72; SD of phosphate=0.69
Kidney Int. Author manuscript; available in PMC 2013 December 01.
